UGT2B7

UGT2B7 is a UDP-glucuronosyltransferase enzyme that belongs to the UGT2B family. This enzyme plays a crucial role in the phase II metabolism of various endobiotics and xenobiotics, specifically in the glucuronidation of fatty acid and sulfonylurea derivatives.

UGT2B7 is widely expressed in human tissues, including the liver, lung, and small intestine. It is involved in the metabolism of several clinically important compounds, including sulindac, bupropion, and tofisopam. The enzyme's activity has also been implicated in the glucuronidation of various endogenous compounds, such as lipoxins and prostaglandin metabolites.

Research has shown that UGT2B7 polymorphisms can affect the metabolism and efficacy of various medications. These polymorphisms can lead to changes in the enzyme's activity, resulting in altered glucuronidation rates. This can affect the pharmacokinetics of administered drugs, leading to potential changes in efficacy or toxicity. Additionally, variations in UGT2B7 gene expression have been observed in individuals with certain diseases, such as non-alcoholic fatty liver disease.

UGT2B7 has been studied in various contexts, including pharmacogenomics and toxicology. Its role in the metabolism of bioactive lipids has also been explored, with implications for understanding the biochemical pathways involved in inflammation and other physiological processes.

Further research is needed to fully elucidate the functional significance of UGT2B7. However, its involvement in the metabolism of medication and endogenous compounds makes it an important enzyme in the field of pharmacology and biochemistry.